The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A randomized trial of mesenchymal stem cells in multiple system atrophy
Open accessAbstract
Objective: Neuroprotective or regenerative strategies are invaluable in multiple system atrophy (MSA) due to its rapid progression with fatal prognosis. We evaluated the efficacy of autologous mesenchymal stem cells (MSC) in patients with MSA‐cerebellar type (MSA‐C). Methods: Thirty‐three patients with probable MSA‐C and baseline unified MSA rating scale (UMSARS) scores ranging from 30 to 50 were randomly assigned to receive MSC (4 × 10 7 /injection) via intra‐arterial and intravenous routes or placebo. The primary outcome was change in the total UMSARS scores from baseline throughout a 360‐day follow‐up period between groups. Secondary outcomes were changes in the UMSARS part II scores, cerebral glucose metabolism, gray matter density, and cognitive performance over a 360‐day period. Results: The mixed model analysis of neurological deficits revealed a significant interaction effect between treatment group and time, suggesting that the MSC group had a smaller increase in total and part II UMSARS scores compared with the placebo group ( p = 0.047 and p = 0.008, respectively). Cerebral glucose metabolism and gray matter density at 360 days relative to the baseline were more extensively decreased in the cerebellum and the cerebral cortical areas, along with greater deterioration of frontal cognition in the placebo group compared with the MSC group. We found no serious adverse effects that were directly related to MSC treatment. However, intra‐arterial infusion resulted in small ischemic lesions on magnetic resonance imaging. Interpretation: MSC therapy could delay the progression of neurological deficits in patients with MSA‐C, suggesting the potential of MSC therapy as a treatment candidate of MSA. ANN NEUROL 2012;72:32–40
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mesenchymal stem cells as trophic mediators
Caplan, A. I., & Dennis, J. E. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20886 · Cited by 2,992
Shults, C. W., Rockenstein, E., Crews, L., Adame, A., Mante, M., Larrea, G., Hashimoto, M., Song, D., Iwatsubo, T., Tsuboi, K., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3527-05.2005 · Cited by 254
Cited by
Fanciulli, A., & Wenning, G. K. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1311488 · Cited by 809
Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices
Sharma, R. R., Pollock, K., Hubel, A., & McKenna, D. (2014) · Transfusion · doi:10.1111/trf.12421 · Cited by 430
Petrou, P., Gothelf, Y., Argov, Z., Gotkine, M., Levy, Y. S., Kassis, I., Vaknin-Dembinsky, A., Ben-Hur, T., Offen, D., Abramsky, O., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.4321 · Cited by 303
Thompson, M., Mei, S. H. J., Wolfe, D., Champagne, J., Fergusson, D., Stewart, D. J., Sullivan, K. J., Doxtator, E., Lalu, M., English, S. W., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2019.100249 · Cited by 283
Poewe, W., Stankovic, I., Halliday, G., Meissner, W. G., Wenning, G. K., Pellecchia, M. T., Seppi, K., Palma, J.-A., & Kaufmann, H. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00382-6 · Cited by 279
Metadata
- Authors
- Lee, P. H., Lee, J. E., Kim, H., Song, S. K., Lee, H. S., Nam, H. S., Cheong, J., Jeong, Y., Park, H., Kim, D. J., Nam, C. M., Lee, J. D., Kim, H. O., & Sohn, Y. H.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2012-07
- Volume
- 72
- Issue
- 1
- Pages
- 32-40
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1991849900
- Cited by
- 234
- References
- 2
- FWCI
- 9.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized trial of mesenchymal stem cells in multiple system atrophy. https://app.cochat.ai/papers/10.1002/ana.23612
- The paper
- Lee, P. H., Lee, J. E., Kim, H., Song, S. K., Lee, H. S., Nam, H. S., Cheong, J., Jeong, Y., Park, H., Kim, D. J., Nam, C. M., Lee, J. D., Kim, H. O., & Sohn, Y. H. (2012). A randomized trial of mesenchymal stem cells in multiple system atrophy. Annals of Neurology. https://doi.org/10.1002/ana.23612
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.